HCEG Healthcare Ent.

 

TIDMHCEG 
 
RNS Number : 7916J 
Healthcare Enterprise Group PLC 
07 April 2010 
 

 
                                                                   07 April 2010 
 
                        Healthcare Enterprise Group PLC 
                                  (AIM: HCEG) 
 
                    ("Healthcare Enterprise" or the "Group") 
 
                Fertiligent medical device receives FDA approval 
 
Healthcare Enterprise, an international healthcare group, is pleased to announce 
that Reproductive Sciences Limited ("RSL" or "the Company"), in which it holds a 
27% interest, has reported that its Fertiligent artificial insemination device 
has received formal approval from the US Food and Drugs Administration ("FDA") 
for its sale in the United States. 
 
Highlights: 
 
·      FDA approval received 
 
·      European CE approval for the final model received in March 2010 
 
·      Manufacturing & assembly agreement signed with Catheter Research, Inc of 
Indianapolis, Indiana, USA 
 
·      Discussions underway to appoint US and international distributors with 
the aim of commencing sales later in 2010 
 
RSL holds the worldwide sales and marketing rights to Fertiligent's products, 
including the "Evie" device. HCEG has contributed management oversight to RSL, 
with direct private investment from funders including Nigel Wray. 
 
RSL has focussed on Fertiligent's "Evie" product, a high quality, low cost 
intrauterine sperm pump to help assist infertile couples conceive. From initial 
trials conducted in Germany and Israel, Fertiligent offers infertile couples an 
enhanced intrauterine insemination success rate and the chance of avoiding 
invasive and costly artificial reproductive techniques such as in vitro 
fertilisation. 
 
The Company, RSL, owns 45% of the issued capital in the Israeli Fertiligent 
Limited company, with options to increase that holding to 78% of the fully 
diluted capital. RSL also owns the exclusive, worldwide sales & marketing rights 
to the Israeli Fertiligent company's products. 
 
Lyndon Gaborit, Executive Deputy Chairman of Healthcare Enterprise, commented: 
 
"We are delighted that this critical milestone has been achieved for the 
Fertiligent 'Evie' medical device. FDA approval, and the recently received CE 
approval for the final production version, significantly reduces risk and paves 
the way for a roll out of this exciting product around the world. Women's 
reproductive health is a significant and increasing market and this new product, 
which provides couples with a low cost alternative to existing reproduction 
methods such as IVF, should, we believe, find good market acceptance with 
associated returns to RSL's investors, including HCEG." 
 
 
For further information, please contact: 
 
+-----------------------------------+-------------------------+-----+ 
| Healthcare Enterprise Group PLC   |                         |     | 
| Lyndon Gaborit                    | Tel:  +44 (0)20 7680    |     | 
|                                   | 3649                    |     | 
+-----------------------------------+-------------------------+-----+ 
| Daniel Stewart & Company plc      | Tel  + 44 (0)20 7776 6550     | 
| Andrew Edwards/Emma Earl          |                               | 
|                                   |                               | 
+-----------------------------------+-------------------------------+ 
| Bishopsgate Communications        |                         |     | 
| Robyn Samuelson / Giang Nguyen    | Tel: +44 (0)20 7562     |     | 
|                                   | 3355                    |     | 
|                                   |                         |     | 
+-----------------------------------+-------------------------+-----+ 
Note to Editors 
 
Healthcare Enterprise 
 
Healthcare Enterprise Group PLC (HCEG) is a healthcare investment group which 
invests in synergistic products and services within the healthcare industry. It 
currently has two main investments: 
 
·      Ebiox Limited - Patented decontamination and disinfectant products that 
are safe and alcohol free but substantially more effective than conventional 
methods at destroying embedded microorganisms. The Ebiox range includes hand 
hygiene products, surface disinfectants and products to clean and decontaminate 
surgical instruments. HCEG owns 20% of Ebiox Limited. 
 
·      Reproductive Sciences Limited - Innovative slow release pump for 
intrauterine insemination, proven to significantly enhance pregnancy success 
rates. HCEG owns 27% of the Company. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 MSCUGUUWCUPUGBQ 
 

Healthcare Enterprise (LSE:HCEG)
Gráfica de Acción Histórica
De May 2024 a Jun 2024

Healthcare Enterprise (LSE:HCEG)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024